Literature DB >> 24559907

Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial.

Francesco Travaglino1, Veronica Russo2, Benedetta De Berardinis3, Filippo Numeroso4, Pamela Catania5, Gianfranco Cervellin6, Stefano Geniere Nigra7, Francesco Geraci8, Maria Antonietta Bressan9, Stefania Guerrini10, Mario Cavazza11, Christian Folli12, Valter Monzani13, Stefania Battista14, Giulio Mengozzi15, Paola Noto16, Giuseppe Carpinteri17, Andrea Semplicini18, Federica Stella19, Stella Ingrassia20, Paolo Moscatelli21, Patrizia Giuntini22, Gerardo Salerno23, Patrizia Cardelli24, Salvatore Di Somma25.   

Abstract

INTRODUCTION: Mid-regional pro-atrial natriuretic peptide (MR-proANP), procalcitonin (PCT), and mid-regional pro-adrenomedullin (MR-proADM) demonstrated usefulness for management of emergency department patients with dyspnea.
METHODS: To evaluate in patients with dyspnea, the prognostic value for 30 and 90 days mortality and readmission of PCT, MR-proADM, and MR-proANP, a multicenter prospective study was performed evaluating biomarkers at admission, 24 and 72 hours after admission. Based on final diagnosis, patients were divided into acute heart failure (AHF), primary lung diseases, or both (AHF + NO AHF).
RESULTS: Five hundred one patients were enrolled. Procalcitonin and MR-proADM values at admission and at 72 hours were significantly (P < .001) predictive for 30-day mortality: baseline PCT with an area under the curve (AUC) of 0.70 and PCT at 72 hours with an AUC of 0.61; baseline MR-proADM with an AUC of 0.62 and MR-proADM at 72 hours with an AUC of 0.68. As for 90-day mortality, both PCT and MR-proADM baseline and 72 hours values showed a significant (P < .0001) predictive ability: baseline PCT with an AUC of 0.73 and 72 hours PCT with an AUC of 0.64; baseline MR-proADM with an AUC of 0.66 and 72 hours MR-proADM with an AUC of 0.71. In AHF, group biomarkers predicted rehospitalization and mortality at 90 days, whereas in AHF + NO AHF group, they predict mortality at 30 and 90 days.
CONCLUSIONS: In patients admitted for dyspnea, assessment of PCT plus MR-proADM improves risk stratification and management. Combined use of biomarkers is able to predict in the total cohort both rehospitalization and death at 30 and 90 days.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24559907     DOI: 10.1016/j.ajem.2013.12.045

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  8 in total

Review 1.  Biomarkers for risk prediction in acute decompensated heart failure.

Authors:  A Rogier van der Velde; Wouter C Meijers; Rudolf A de Boer
Journal:  Curr Heart Fail Rep       Date:  2014-09

Review 2.  Biomarkers in heart failure: the past, current and future.

Authors:  Michael Sarhene; Yili Wang; Jing Wei; Yuting Huang; Min Li; Lan Li; Enoch Acheampong; Zhou Zhengcan; Qin Xiaoyan; Xu Yunsheng; Mao Jingyuan; Gao Xiumei; Fan Guanwei
Journal:  Heart Fail Rev       Date:  2019-11       Impact factor: 4.214

3.  Plasma bioactive adrenomedullin as a prognostic biomarker in acute heart failure.

Authors:  Wesley H Self; Alan B Storrow; Oliver Hartmann; Tyler W Barrett; Gregory J Fermann; Alan S Maisel; Joachim Struck; Andreas Bergmann; Sean P Collins
Journal:  Am J Emerg Med       Date:  2015-10-24       Impact factor: 2.469

Review 4.  The role of procalcitonin in acute heart failure patients.

Authors:  Martin Möckel; Julia Searle; Alan Maisel
Journal:  ESC Heart Fail       Date:  2017-07-18

5.  Can mid-regional pro-adrenomedullin (MR-proADM) increase the prognostic accuracy of NEWS in predicting deterioration in patients admitted to hospital with mild to moderately severe illness? A prospective single-centre observational study.

Authors:  Sara Graziadio; Rachel Amie O'Leary; Deborah D Stocken; Michael Power; A Joy Allen; A John Simpson; David Ashley Price
Journal:  BMJ Open       Date:  2019-02-22       Impact factor: 2.692

6.  Prognostic value of biomarkers after cardiopulmonary bypass in pediatrics: The prospective PANCAP study.

Authors:  Sara Bobillo-Perez; Iolanda Jordan; Patricia Corniero; Monica Balaguer; Anna Sole-Ribalta; Maria Esther Esteban; Elisabeth Esteban; Francisco Jose Cambra
Journal:  PLoS One       Date:  2019-06-17       Impact factor: 3.240

7.  Extracellular Vesicle Proteins Associated with Systemic Vascular Events Correlate with Heart Failure: An Observational Study in a Dyspnoea Cohort.

Authors:  Ya-Nan Zhang; Flora Vernooij; Irwani Ibrahim; Shirley Ooi; Crystel M Gijsberts; Arjan H Schoneveld; Kuan Win Sen; Hester M den Ruijter; Leo Timmers; Arthur Mark Richards; Chun Tzen Jong; Ibrahim Mazlan; Jiong-Wei Wang; Carolyn S P Lam; Dominique P V de Kleijn
Journal:  PLoS One       Date:  2016-01-28       Impact factor: 3.240

8.  The association of serum procalcitonin and high-sensitivity C-reactive protein with pneumonia in elderly multimorbid patients with respiratory symptoms: retrospective cohort study.

Authors:  Antonio Nouvenne; Andrea Ticinesi; Giuseppina Folesani; Nicoletta Cerundolo; Beatrice Prati; Ilaria Morelli; Loredana Guida; Fulvio Lauretani; Marcello Maggio; Rosalia Aloe; Giuseppe Lippi; Tiziana Meschi
Journal:  BMC Geriatr       Date:  2016-01-15       Impact factor: 3.921

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.